Sanofi Ventures
Profile, fund size and portfolio
Sanofi Ventures is the corporate venture arm of Sanofi (biopharmaceuticals). It was founded in 2012 and is based in Cambridge, United States. It invests from Seed to Series B in rare diseases, immunology and inflammation, oncology.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series B |
| Sectors | Rare diseases, Immunology and inflammation, Oncology, Cell and gene therapy, Vaccines, Digital health and data science |
| Geography | North America, Europe, Asia, Oceania, Middle East and Africa |
| Offices | Cambridge, United States, Paris, France |
Sources: S4 Sanofi Ventures approach; S3 Sanofi Ventures portfolio (status and location per card).
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Active | 60 | 71.4% |
| Exited | 24 | 28.6% |
Status as the firm tags it
Sources: S3 Sanofi Ventures portfolio (status and location per card).
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 1.4bn+ | Assets under management | Stated by the firm or its parent | S5 |
| Companies backed | 70+ | companies | Stated by the firm | S5 |
| IPOs | 16 | IPOs | Stated by the firm | S3 |
| M&A exits | 8 | exits | Stated by the firm | S3 |
| Companies on the firm's portfolio page | 84 | companies | Counted from the firm's own list | S3 |
Sources: S5 Sanofi press release: additional USD 625 million to Sanofi Ventures (24 Sep 2025); S3 Sanofi Ventures portfolio (status and location per card).
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Sanofi | Single source | S5 |
| Parent industry | Biopharmaceuticals | Single source | S5 |
| Founded | 2012 | Single source | S5 |
| Headquarters | Cambridge, United States | Single source | S2 |
| Status | Active | Single source | S5 |
| Capital source | Parent company only | Single source | S5 |
| Headline size | USD 1.4bn+ (Assets under management) | Single source | S5 |
| Companies backed | 70+ | Single source | S5 |
| Exits | 24 total, 16 IPOs, 8 M&A | Single source | S3 |
| People on the team page | 12 | Single source | S2 |
| Stages | Seed, Series A, Series B | Single source | S4 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
| Company | Type | Year | Acquirer or exchange | Price | Source |
|---|---|---|---|---|---|
| Bluebird Bio | IPO | S3 | |||
| Common Sensing | Acquisition | S3 | |||
| Curevo Vaccine | Acquisition | S3 | |||
| Curisium | Acquisition | S3 | |||
| Escient Pharmaceuticals | Acquisition | S3 | |||
| Fate Therapeutics | IPO | S3 | |||
| Fulcrum Therapeutics | IPO | S3 | |||
| GlycoMimetics | IPO | S3 | |||
| Icosavax | Acquisition | S3 | |||
| Immune Design | IPO | S3 | |||
| Inozyme Pharma | Acquisition | S3 | |||
| KaloBios | IPO | S3 | |||
| Kymera Therapeutics | IPO | S3 | |||
| LAVA Therapeutics | IPO | S3 | |||
| Lumena Pharmaceuticals | Acquisition | S3 |
Portfolio
The firm's portfolio page lists 84 companies: 60 active, 24 exited.S3
The firm also states 70+ companies backed. The page list and the stated total measure different things.S5
| Tag | Companies | Share |
|---|---|---|
| Active | 60 | 71.4% |
| Exited | 24 | 28.6% |
Every company on the Sanofi Ventures list
84 companies, as listed on the firm's own website: 60 active, 24 exited.S3 Read the firm's list.
Active 60
- abcuro
- AdvanCell Isotopes
- Aetion
- Aliada Therapeutics
- Atalanta Therapeutics
- Attovia Therapeutics
- Avilar Therapeutics
- Bionyra
- BranchLab
- Carbon Health
- Character Biosciences
- Click Therapeutics
- Diagonal Therapeutics
- Draig Therapeutics
- Eligo Bioscience
- Empatica
- Epicrispr Biotechnologies
- Evidation
- Expansion Therapeutics
- Expedition Therapeutics
- Glycomine
- Granite Bio
- i2O Therapeutics
- Imbria Pharmaceuticals
- Korsana Biosciences
- Latigo Bio
- Lifordi Immunotherapeutics
- Matchpoint Therapeutics
- Medisafe
- Memento Medicines
- Minervax
- Mirador Therapeutics
- Muna Therapeutics
- Navitor
- NextPoint Therapeutics
- Normunity
- Nucleai
- Nura Bio
- Nuvig Therapeutics
- Odyssey Therapeutics
- Omada Health
- OMass Therapeutics
- Q32 Bio
- QuantHealth
- QuantX Biosciences
- QurAlis
- ReCode Therapeutics
- Rezera
- Rome Therapeutics
- Science37
- Splice Bio
- Star Therapeutics
- Sudo Biosciences
- T-Therapeutics
- Therini Bio
- Tisento Therapeutics
- Trial Library
- Veralox Therapeutics Inc
- Windward Bio
- Zag Bio
Exited 24
- Bluebird Bio
- Common Sensing
- Curevo Vaccine
- Curisium
- Escient Pharmaceuticals
- Fate Therapeutics
- Fulcrum Therapeutics
- GlycoMimetics
- Icosavax
- Immune Design
- Inozyme Pharma
- KaloBios
- Kymera Therapeutics
- LAVA Therapeutics
- Lumena Pharmaceuticals
- Lysosomal Therapeutics
- MacroGenics
- Ovid Therapeutics
- Proteostasis Therapeutics
- Selecta Biosciences
- Ultragenyx
- Unum Therapeutics
- Voluntis
- Yumanity Therapeutics
For founders
| Item | What the firm says | Source |
|---|---|---|
| Stages | Seed, Series A, Series B | S4 |
| Leads rounds | Yes. "leading financings, serving on boards" | S4 |
| Pitch page | www.sanofiventures.com/team | S2 |
Fund vehicles
| Vehicle | Size | Year | Note | Source |
|---|---|---|---|---|
| Additional multi-year commitment (Sep 2025) | USD 625M | 2025 | Brings total assets under management to over USD 1.4 billion | S5 |
History
- Sanofi Ventures inception (Sep 2025 release: since its inception in 2012).S5
- Three realized exits with a combined acquisition value of USD 3.25 billion (per Sep 2025 release).S5
- Additional USD 625 million multi-year commitment from Sanofi; total assets under management over USD 1.4 billion (24 Sep).S5
Where sources disagree
Official pages
Read the firm's own pages for current information.
- Website www.sanofiventures.com
- Portfolio www.sanofiventures.com/portfolio
- Pitch page www.sanofiventures.com/team
Sources
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Sanofi Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.